{'fraction_non_alphanumeric': 0.018413597733711047, 'fraction_numerical': 0.0056657223796034, 'mean_word_length': 5.607476635514018, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of childhood lymphangiomas with interferon-alpha.

PURPOSE
Nonsurgical treatment of lymphangiomas has shown limited efficacy and often carries unacceptable toxicities, demonstrating the need for a more effective, less toxic therapy.


PATIENTS AND METHODS
We describe two patients with lymphangiomatosis treated for 12 to 40 months with recombinant interferon-alpha.


RESULTS
Both patients demonstrated stabilization or marked improvement of disease, based on clinical and radiologic findings, with minimal toxicity.


CONCLUSIONS
The favorable responses to interferon-alpha therapy in these two cases suggest that this is an effective and well-tolerated treatment for lymphangiomas in children.